Thomas Ciulla

Thomas Ciulla

Company: Clearside Bio

Job title: Chief Medical & Development Officer

Seminars:

Suprachoroidal Delivery – A Novel Approach 2:30 pm

Potential advantages of suprachoroidal delivery include targeting of affected chorioretinal tissues for potential efficacy benefits, compartmentalization away from unaffected tissues for potential safety benefits, and bioavailability Durability for small molecule suspensions is driven by its relative insolubility and particle size Multiple classes of therapeutic agents are being assessed suprachoroidally in clinical trials globally, including a…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.